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Although mycophenolate mofetil (MMF) has replaced corticosteroids as immunosuppression in cord blood
transplantation (CBT), optimal MMF dosing has yet to be established. We intensiﬁed MMF dosing from every
12 to every 8 hours to augment graft-versus-host disease (GVHD) prophylaxis in double-unit cord blood
transplantation (dCBT) and evaluated outcomes according to the total daily MMF dose/kg in 174 dCBT re-
cipients (median age, 39 years; range, 1 to 71) who underwent transplantation for hematologic malignancies.
Recipients of an MMF dose  the median (36 mg/kg/day) had an increased day 100 grade III and IV acute
GVHD (aGVHD) incidence compared with patients who received >36 mg/kg/day (24% versus 8%, P ¼ .008).
Recipients of  the median dose who had highly HLA allele (1 to 3 of 6) mismatched dominant units had the
highest day 100 grade III and IV aGVHD incidence of 37% (P ¼ .009). This ﬁnding was conﬁrmed in multi-
variate analysis (P ¼ .053). In 83 patients evaluated for mycophenolic acid (MPA) troughs, those with a mean
week 1 and 2 trough < .5 mg/mL had an increased day 100 grade III and IV aGVHD of 26% versus 9% (P ¼ .063),
and those who received a low total daily MMF dose and had a low mean week 1 and 2 MPA trough had a 40%
incidence (P ¼ .008). Higher MMF dosing or MPA troughs had no impact on engraftment after myeloablation.
This analysis supports intensiﬁed MMF dosing in milligram per kilogram per day and MPA trough level
monitoring early after transplantation in dCBT recipients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Mycophenolate mofetil (MMF) is an inactive morpholi-
noethyl ester prodrug that inhibits the proliferation of T and B
lymphocytes and is designed to enhance the bioavailability of
the active form, mycophenolic acid (MPA). MMF has been
a successful immunosuppressive agent in adult donor
allogeneic hematopoietic stem cell transplantation [1].edgments on page 925.
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ty for Blood and Marrow Transplantation.Consequently, MMF was introduced in unrelated donor
cord blood (CB) transplantation (CBT) to avoid the multiple
toxicities of corticosteroids [2]. However, some centers
have had concerns that MMF could be associated with
myelosuppression in CBT recipients [3,4]. Furthermore, MPA’s
pharmacokinetics (PK) are characterized by a high intra- and
inter- patient variability [5,6], and inadequateMPA levels have
been correlated with a reduced efﬁcacy of prophylaxis and
treatment of acute graft-versus-host disease (aGVHD) [7,8].
To augment MMF exposure, MMF has been increased
from 1 g every 12 hours to 1 g every 8 hours in adult allograft
recipients [9-11]. As aGVHD is a leading cause of morbidity
S. Harnicar et al. / Biol Blood Marrow Transplant 21 (2015) 920e925 921and transplantation-related mortality (TRM) in CBT [12-14],
intensiﬁed MMF dosing has also been adopted in CBT [15].
Dosing in patients 50 kg, however, has not taken into ac-
count the recipient’s weight. Hence, the association between
MMF dosing and both aGVHD prevention and the potential
toxicities to the bonemarrow and gastrointestinal tract merit
investigation [16]. As there is also no established target MPA
exposure for CBT recipients, the association betweenMPA PK
parameters and these endpoints also require evaluation. We
have, therefore, investigated the transplantation outcomes in
174 double-unit CBT (dCBT) recipients treated for hemato-
logic malignancies according to the total MMF dose in mil-
ligrams per kilogram per day. We hypothesized that MMF
doses above the median total daily dose would be associated
with a reduced incidence of grade III and IV aGVHD without
an adverse effect upon neutrophil engraftment. In a subset of
patients, the association between total MPA trough levels
and day 100 aGVHD and engraftment was also evaluated.
METHODS
Patients and Graft Characteristics
Patients underwent transplantation at Memorial Sloan Kettering Cancer
Center (MSKCC) between October 1, 2005 andMay 31, 2013. Patients eligible
for this analysis included all consecutive adult and pediatric recipients of
ﬁrst allografts who underwent dCBT for the treatment of hematologic ma-
lignancies with the exclusion of acute leukemia patients who underwent
transplantation with 20% bone marrow blasts. All patients received
double-unit CB grafts per institutional standard practice. CB units were
selected on the basis of 4 to 6 of 6 HLA-A, -B antigen, -DRB1 allele match to
the recipient, a cryopreserved total nucleated cell dose of at least 1.5  107/
kg/unit, and the bank of origin, as previously described [17]. Unit-unit HLA
match was not considered. High resolution HLA-A, -B, -C, -DRB1, and -DQ
allele typing of CB units was performed routinely for research purposes and
usually did not inﬂuence unit selection. All patients provided written
informed consent for transplantation and transplantation outcome analysis
on protocols approved by theMSKCC Institutional Reviewand Privacy Board.
Conditioning and GVHD Prophylaxis
Pretransplantation conditioning varied according to the patient’s age,
diagnosis, remission status, extent of prior therapy, and comorbidities, and
consisted of high-dose, reduced-intensity (but functionally myeloablative),
and nonmyeloablative regimens as previously described [13,18]. Intravenous
calcineurin inhibitors (CNI), predominantly cyclosporine A (CSA), and MMF
comprised GVHD prophylaxis starting on day -3 intravenously with no
antithymocyte globulin. CSAwas dosed to achieve a trough level 200 to 400
ng/mL and tacrolimus was dosed to achieve trough levels of 5 to 12 ng/mL.
Before September 2009, 81 patients (47%) received MMF 1 g intravenously
every 12 hours (those 12 years or <50 kg received 15 mg/kg/dose). From
September 2009, intensiﬁed MMF dosing was instituted to augment GVHD
prophylaxis. Ninety-three patients (53%) received MMF at 1 g intravenously
every 8 hours for patients both >12 years and 50 kg (or 15 mg/kg/dose if
>12 years but <50 kg). Patients 12 years received 20 mg/kg/dose. Gran-
ulocyte colonyestimulating factor (5 mg/kg/day rounded to vial size) was
given after CBT to all patients until neutrophil recovery.
Standard practice to taper MMF was to reduce the dose at approximately
75 to 100 days after transplantation if there was no aGVHD. In patients dosed
every 8 hours, this interval wasmaintained for as long as possible unless there
were adherence problems with this schedule, in which case a switch to twice
daily dosingwasmade. The taper was performed at 10% to 25% decrements in
all patients with the goal of being off MMF by 4 to 6 months; however, this
schedule was ultimately at the physician’s discretion. For example, increased
relapse risk may have resulted in a hastened taper schedule with attention to
the development of aGVHD symptoms. Themost frequent reason to delay the
MMF taper other than aGVHD was signiﬁcant renal impairment preventing
therapeutic cyclosporine levels. Dosing modiﬁcations were very rarely made
for delayed engraftment early after transplantation. However, later in the
transplantation course, dosing reductions were sometimes done for cyto-
penias usually in the context of concurrent valganciclovir therapy.
Sample Collection and Analysis for MPA Trough Levels
Serial weekly total MPA trough levels were collected on days 1, 8, 15, 22,
29, and 36 after dCBT from a subset of 85 patients who underwent trans-
plantation from August 1, 2009 to November 30, 2012. Troughs were eval-
uated because of the substantial logistical advantage over the serial bloodsamples required for area under the curve measurements. Samples were
collected primarily for research purposes. However, in 8 of 85 (9%) patients,
dosing was increased to every 8 hours inweek 2 as a result of week 1 trough
results. Samples of1mL serumwere collected in a no additive red top tube.
Peripheral bloodwas collected in adults, whereas the sample in childrenwas
drawn from a non-MMFeinfused line. The blood was allowed to clot for 20
to 30 minutes at 15C to 28C, centrifuged at 2700 rpm for 10 minutes, and
sent for analysis by liquid chromatographymass spectrometry methodology
at Quest Diagnostics Laboratories, Teterboro, NJ. The result was available
within 3 to 4 days.
Study Deﬁnitions
Neutrophil recoverywas deﬁned as the ﬁrst of 3 consecutive days with an
absolute neutrophil count  .5  109/L, whereas platelet recovery was the
ﬁrst of 3 consecutive days  20  109/L and at least 7 days without trans-
fusion support. Engraftment was deﬁned as sustained donor-derived count
recovery with donor chimerism > 90% (both units combined). aGVHD was
diagnosed clinically with histologic conﬁrmation when appropriate. The
grade of aGVHD was based on the International Bone Marrow Transplant
Registry classiﬁcation [19], except grades A to D were labeled grades I to IV.
Grading was reviewed by a transplantation clinician panel to reach a
consensus of maximum aGVHD grade. Chronic GVHDwas deﬁned according
to the National Institutes of Health consensus criteria [20]. Relapse was
deﬁned as recurrence or progression of disease over pretransplantation
baseline, and TRM was death from any cause in continued remission.
Progression-free survival (PFS) was deﬁned according to standard criteria.
Statistical Analysis
For analysis purposes, patients were a priori divided into 2 dosing
groups: above or below the median total daily milligram per kilogramMMF
dose. The strategy to analyze outcomes according to above versus below the
median total daily dose was chosen, as deriving a threshold based on the
observed data would require a separate validation cohort. Descriptive ana-
lyses were performed for patient demographics and differences across low
versus high MMF groups and compared using the Wilcoxon rank-sum test
for continuous covariates. Chi-square and Fisher’s exact test were used for
categorical covariates as indicated. The cumulative incidence method for
competing risks was used to calculate the cumulative incidence of
engraftment, GVHD, TRM, and relapse. Gray’s test was used to compare the
incidence of select outcomes across MMF dose levels. PFS was calculated
using Kaplan-Meier methodology and compared across MMF dose levels
using a log-rank test.
In the subset analyses of MPA trough levels, descriptive statistics sum-
marized the changes in MPA trough levels over the ﬁrst 6 weeks after
transplantation and the trends across age and conditioning regimens. Fisher’s
exact test evaluated associations between patient clinical factors and mean
week 1 and 2 trough levels dichotomized at .5 mg/mL. To evaluate the asso-
ciation betweenMPA trough levels and dCBToutcomes,mean levels ofweek 1
and week 2 combined were dichotomized at <.5 mg/mL and .5 mg/mL for
efﬁcacy and <2 mg/mL and2 mg/mL for toxicity. Starting from a landmark of
2 weeks after transplantation, cumulative incidence functions and Gray’s test
were used to estimate and compare engraftment and aGVHD by mean MPA
trough levels. All analyseswere conducted using R statistical software, version
3.1.1 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Comparison of Patient Characteristics According to MMF
Dosing
One hundred seventy-four patients were analyzed. The
majority (n¼ 136, 78%) received myeloablative conditioning.
The median total daily dose of MMF was 36 mg/kg. Patients
who received low (below the median) and high (above the
median) total daily doses were comparable in terms of age,
recipient cytomegalovirus (CMV) status, disease type and
risk, conditioning regimen intensity, and graft characteristics
(dominant or engrafting unit infused CD34þ cell dose and 6
HLA-allele match) (Table 1). However, patients in the low
dosing group were more likely to be male, heavier, and
receive MMF every 12 hours.
Association between MMF Dosing and aGVHD
Transplantation outcomes according to MMF dosing
below versus above the median total daily MMF dose/kg are
shown in Table 2. There was no difference in the cumulative
Table 2
dCBT Outcomes by Total Daily MMF Dose per Kilogram*
Variable 95% CI P Value
Day 45 neutrophil engraftmenty
Low MMF dose (n ¼ 78) 95% (86-98) .990
High MMF dose (n ¼ 58) 95% (83-99)
Day 100 aGVHD II-IV
Low MMF dose (n ¼ 101) 53% (42-62) .345
High MMF dose (n ¼ 73) 47% (35-58)
Day 100 aGVHD III-IV
Low MMF dose (n ¼ 101) 24% (16-33) .008
High MMF dose (n ¼ 73) 8% (3-16)
1-yr chronic GVHD
Low MMF dose (n ¼ 101) 12% (7-19) .422
High MMF dose (n ¼ 73) 11% (5-20)
Day 180 TRM
Low MMF dose (n ¼ 101) 20% (13-28) .371
High MMF dose (n ¼ 73) 21% (12-31)
1-yr relapse
Low MMF dose (n ¼ 101) 14% (8-21) .518
High MMF dose (n ¼ 73) 15% (8-24)
1-yr PFS
Low MMF dose (n ¼ 101) 63% (53-72) .225
High MMF dose (n ¼ 73) 59% (47-69)
* Below versus above the median.
y Myeloablative CBT recipients only.
Table 3
Univariate Analysis of Day 100 Grade III-IV aGVHD according to Patient and
Graft Characteristics
Variable Cumulative
Incidence
(95% CI)
P Value
Age
0-15 yr (n ¼ 35) 26% (13-41) .129
16 yr (n ¼ 139) 15% (10-22)
Recipient gender
Male (n ¼ 97) 25% (17-34) .003
Female (n ¼ 77) 8% (3-15)
Engrafting unit gender in males*
Male (n ¼ 54) 26% (15-38) .478
Female (n ¼ 40) 20% (9-34)
Median weight, kg
67.5 (n ¼ 87) 17% (10-26) .973
>67.5 (n ¼ 87) 17% (10-26)
Recipient CMV serostatus
Negative (n ¼ 78) 24% (16-34) .026
Positive (n ¼ 96) 12% (6-19)
Conditioning intensity
Myeloablative (n ¼ 136) 18% (12-25) .800
Nonmyeloablative (n ¼ 38) 16% (6-29)
Median MMF dose (mg/kg/d)
36 (n ¼ 101) 24% (16-33) .008
>36 (n ¼ 73) 8% (3-16)
Dominant unit-recipient 6-allele HLA Match
1-3/6 (n ¼ 48) 25% (14-38) .105
4-6/6 (n ¼ 126) 14% (9-21)
Median total daily MMF dose and dominant unit-recipient
6 allele HLA match
Low (36) and worse (1-3/6) (n ¼ 30) 37% (20-54) .009
High (>36) and worse (1-3/6) (n ¼ 18) 6% (0-23)
Low (36) and better (4-6/6) (n ¼ 71) 18% (10-28)
High (>36) and better (4-6/6) (n ¼ 55) 9% (3-19)
* Dominant unit gender unknown in 3 patients.
Table 1
Patient and Graft Demographics according to Total Daily MMF Dose per
Kilogram*
Characteristic mTDD  36
(n ¼ 101)
mTDD > 36
(n ¼ 73)
P Value
Age, median (range), yr 42 (1-66) 36 (2-71) .181
Recipient gender, n (%)
Male 70 (69%) 27 (37%) <.001
Female 31 (31%) 46 (63%)
Weight, median (range), kg
Overall 80 (7-125) 54 (10-77) <.001
Male 82 (7-125) 63 (11-76) <.001
Female 70 (13-104) 53 (10-77) <.001
Recipient CMV serostatus, n (%)
Negative 51 (51%) 27 (37%) .107
Positive 50 (50%) 46 (63%)
Disease type, n (%)
Acute leukemia 52 (52%) 48 (66%) .173
MDS/CML/other MPD 7 (7%) 3 (4%)
NHL/HL/CLL 42 (42%) 22 (30%)
Disease risk, n (%)
Standard 11 (11%) 9 (12%) .958
High 90 (89%) 64 (88%)
Conditioning intensity, n (%)
Myeloablative 78 (77%) 58 (80%) .869
Nonmyeloablative 23 (23%) 15 (21%)
Dosing interval, n (%)
Every 12 h 71 (70%) 10 (14%) <.001
Every 8 h 30 (30%) 63 (86%)
Dominant unit median infused CD34þ cell dose (range),  105/kg
Larger unit 1.30 (.26-6.42) 1.24 (.41-4.77) .793
Smaller unit .68 (.13-1.52) .66 (.08-2.12) .976
Unit 6 allele HLA match, n (%)y
1-3/6 75 (37%) 42 (29%) .130
4-6/6 127 (63%) 104 (71%)
mTDD indicates median total daily dose; MDS, myelodysplastic syndrome;
CML, chronic myelogenous leukemia; MPD, myeloproliferative disorder;
NHL, non-Hodgkin’s lymphoma; HL, Hodgkin’s lymphoma; CLL, chronic
lymphocytic leukemia.
* Below versus above the median total daily dose in milligram per
kilogram.
y The HLA match grade reﬂects 202 units in the low MMF patient group
and 146 units in the high group.
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high dosing groups (53% versus 47%, P ¼ .345). The incidence
of severe (grade III and IV) aGVHD at day 100, however, was
3-fold higher in recipients of a total daily MMF dose below
the median versus those in the high group (24% versus 8%,
P ¼ .008). One-year chronic GHVD was not different in the 2
groups (12% versus 11%, P ¼ .422).
In univariate analysis of variables potentially associated
with the incidence of day 100 grade II to IV aGHVD, aGVHD
was associated with gender (57% in male versus 42% in fe-
male patients, P ¼ .027) and CMV serostatus (58% in sero-
negative versus 44% in seropositive dCBT recipients, P ¼
.032). The results of univariate analysis of grade III and IV
aGVHD are shown in Table 3. Male gender was associated
with a higher incidence of severe aGVHD (25% versus 8%, P ¼
.003). Despite males being heavier, recipient weight (below
or above the median) was not signiﬁcant, and analyzing the
patient’s weight as a continuous variable or in quartiles also
showed no differences in aGVHD incidence. The association
between male gender and grade III-IV aGVHD persisted in
both patients whose weight was below the median or in the
subset whose weight was above the median. Additionally,
among male patients only, there was no association between
weight and grade III-IV aGVHD (data not shown). Finally, in
male patients there was no difference in the gender of the
dominant unit and, therefore, gender mismatch did not
explain increased aGVHD incidence in males.In univariate analysis, there was also a signiﬁcant asso-
ciation between grade III and IV aGVHD and the combination
of MMF dose and dominant unit-recipient HLA match (P ¼
.009, Table 3). Recipients of total daily MMF doses below the
median who had dominant units with a high degree of HLA
mismatch (n ¼ 30) had the highest incidence of day 100
grade III and IV aGVHD at 37%. In contrast, patients with a
Table 4
Multivariate Analysis of Variables Potentially Associated with Day 100 Grade
III-IV aGVHD Risk
Variable HR (95% CI) P Value
Age, yr
0-15 (n ¼ 35) Reference .217
16 (n ¼ 139) .58 (.24-1.38)
Recipient gender
Male (n ¼ 97) Reference .041
Female (n ¼ 77) .38 (.15-.96)
Recipient CMV serostatus
Negative (n ¼ 78) Reference .190
Positive (n ¼ 96) .58 (.26-1.31)
Median total daily MMF dose and dominant unit-recipient
6-allele HLA match
Low (36) and worse (1-3/6) (n ¼ 30) Reference .053
High (>36) and worse (1-3/6) (n ¼ 18) .23 (.03-1.84)
Low (36) and better (4-6/6) (n ¼ 71) .46 (.20-1.07)
High (>36) and better (4-6/6) (n ¼ 55) .26 (.09-.75)
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Severe aGVHD incidence in those with a low MMF dose but
better HLA alleleematched engrafting unit was intermediate
at 18%. Differences in severe aGVHD by dominant unit-
recipient HLA match alone did not reach signiﬁcance.
In a multivariate analysis that included age, gender, CMV
serostatus, and the 4 category combination of MMF dose and
HLAmismatch,maleswere signiﬁcantlymore likely to develop
grade III and IV aGVHD (P¼ .041) (Table 4). The risk of grade III
and IV aGVHD also differed by MMF dose and degree of HLA
mismatch combination, with the highest risk in those who
received a lowMMFdose and higher HLAmismatch (P¼ .053).Association between MMF Dosing and Engraftment and
Survival Endpoints
Given that most nonmyeloablative dCBT recipients had
transient autologous recovery, the effect of MMF dosing on
donor engraftment was only compared among myeloablated
dCBT recipients. The cumulative incidences of day 45
neutrophil engraftment were nearly identical regardless of
MMF dosing, with each being 95% in the low and high MMF
dosing groups atmedians of 23 and 24 days, respectively (P¼
.990) (Table 2). The cumulative incidences of day 180 platelet
engraftment were also similar: 82% (95% conﬁdence interval
[CI], 71% to 89%;median, 49 days; range, 29 to 162) in the lowFigure 1. (A) Cumulative incidence of day 100 II to IV aGVHD by MPA trough level (n ¼
mg/mL had no association with grades II to IV aGVHD by day 100. (B) Cumulative inc
landmark analysis, the incidence of grade III and IV aGVHD at day 100 was lower indose group and 86% (95% CI, 72% to 94%; median, 46 days;
range, 30 to 137) in the high dose group (P ¼ .270).
There were no signiﬁcant differences in the cumulative
incidences of TRM or relapse by dosing group, and the PFS
were also similar (Table 2). Of 49 TRM deaths, GVHD was the
most common cause (n¼ 22) followed by organ toxicity (n¼
13). Infection as the primary cause of death was uncommon,
occurring in only 7 patients overall. There were no differ-
ences in the percentage of patients dying of GVHD in low
versus high MMF dosing groups. Eleven of 22 patients who
died of GVHD did so before day 180. Of these 22 patients,
aGVHD onset was before day 100 in all but 1 patient, and all
22 patients who died of GVHD had either aGVHD (n ¼ 20) or
aGVHD followed by overlap syndrome (n ¼ 2).
Subset Analysis of Total MPA Trough Levels
Serial MPA troughs during weeks 1 to 6 were available in
85 patients. These showed an increase in exposure over time
for all patients: week 1 median MPA trough was .9 mg/mL and
week 6 median was 1.3 mg/mL. Two patient groups had
consistently lower levels in the ﬁrst 6 weeks after trans-
plantation: children <16 years of age, whose levels ranged .3
to 1.2 mg/mL lower than adults, and recipients of myeloa-
blative conditioning, whose levels ranged .4 to .8 mg/mL lower
than those who received nonmyeloablative conditioning.
Based on the known importance of therapeutic early
post-transplantation week CNI levels [21], we analyzed day
100 aGVHD risk according to the mean week 1 and 2 MPA
trough levels using a level  .5 mg/mL. We chose this con-
centration because a meanweek 1 and 2 trough> .5 mg/mL is
clinically signiﬁcant for efﬁcacy of aGVHD therapy [8].
Eighty-three patients had complete blood samples in the ﬁrst
2 weeks after transplantation. Clinical factors such as age,
gender, above or below 120% of ideal body weight,
concomitant CNI, and albumin and bilirubin levels above or
below the upper limit of normal were not associated with
trough levels of <.5 or .5 mg/mL, and CNI levels were
therapeutic for all patients in the ﬁrst 2 weeks (data not
shown). Fifty-six of 69 (81%) patients who received MMF
every 8 hours had trough levels  .5 mg/mL compared with 8
of 14 (57%) in the 12-hour dosing group (P ¼ .078).
There was no difference in the cumulative incidence of
day 100 grade II to IV aGVHD in MPA trough level groups of
<.5 and .5 mg/mL (Figure 1A). Patients with troughs of <.583). In a day 14 landmark analysis, mean week 1 and 2 MPA trough levels  .5
idence of day 100 III and IV aGVHD by MPA trough level (n ¼ 83). In a day 14
dCBT recipients with mean week 1 and 2 MPA trough levels  .5 mg/mL.
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26% versus 9% (P¼ .063) (Figure 1B). dCBT recipients (n¼ 10)
who received a low total dailyMMF dose (median of 43mg/
kg/day in this 83 patient subset) and had a lowmeanweek 1
and 2 MPA trough level (<.5 mg/mL) had an incidence of
grade III and IV aGVHD at day 100 of 40% (95% CI, 7% to 73%)
as compared with that of 10% (95% CI, 3% to 16%) in the 73
patients with other dose and trough level combinations (ie,
high MMF dose regardless of trough level or trough  .5 mg/
mL regardless of dose, P ¼ .008).
To evaluate whether high MPA troughs correlated with
myelosuppression or gastrointestinal toxicity, engraftment
and duration of total parenteral nutrition (TPN) were
analyzed. Concentrations of <2 and 2 mg/mL were chosen
because 2 mg/mL have been associated with leukopenia in
solid organ transplant recipients [22]. There was no differ-
ence in the cumulative incidence of day 100 neutrophil
engraftment in myeloablated patients withmeanweek 1 to 2
MPA troughs of <2 and 2 mg/mL: 95% (95% CI, 89% to 100%)
versus 100% (95% CI, 78% to 100%), P ¼ .422. Also in mye-
loablated patients, there were no differences in platelet
engraftment or duration of TPN (data not shown).
DISCUSSION
Although MMF immunosuppression in combination with
a CNI has been used in CBT as aGVHD prophylaxis since the
year 2000 [2], optimal dosing of MMF has not been estab-
lished. In view of the signiﬁcant incidence of aGVHD in our
patient population [13], we have intensiﬁed MMF dosing to
every 8 hours in dCBT recipients. However, in this analysis
we analyzed transplantation outcomes according to the
MMF dose in milligram per kilogram per day, as dosing has
not accounted for recipient weight  50 kg, and dosing in
small children has substantially changed over the time
period of the study. Patients in each milligram per kilogram
per day dosing groups were well matched, strengthening the
multiple signiﬁcant ﬁndings of this analysis. We found re-
cipients who received a low milligram per kilogram per day
dose of MMF had a signiﬁcantly higher incidence of day 100
grade III and IV acute GVHD. Recipients of a low dose who
had a highly HLA alleleemismatched dominant unit were at
the worst risk. Finally, patients with meanweek 1 and 2 MPA
trough concentrations < .5 mg/mL had an increased day 100
grade III and IV aGVHD with no effect on hematopoietic re-
covery or gastrointestinal toxicity, as measured by TPN use.
To our knowledge, this is the ﬁrst large and comprehensive
analysis to address the issue of MMF dosing in milligram per
kilogram per day and include assessment of the clinical sig-
niﬁcance of MPA trough levels early after transplantation in
CBT patients.
Important in this analysis is that when combining the
MMF total daily dose with the degree of dominant unit-
recipient HLA match, we noted that a higher MMF dose
could potentially reduce the detrimental impact of having a
lesser HLA-matched engrafting unit. This is clinically rele-
vant, given our center’s prior report that found a less well-
matched dominant unit was associated with a greater
grade III and IV aGVHD risk [13]. Although our ﬁndings must
be conﬁrmed in larger studies, they suggest that a higher
MMF dose is beneﬁcial in recipients of grafts with a high
degree of HLA mismatch.
Although it is established that small children metabolize
MMF more rapidly than adults, we did not identify a signiﬁ-
cant association between age and grade III and IV aGVHD
(Tables 3 and 4). Thismayhave been due to partial abrogationof aGVHD by the substantial increase in MMF dose in small
children during the study period, and it is an important
question for further investigation. Anunexpectedobservation
in this serieswas thatmale patients had a signiﬁcantly higher
incidence of grade III and IV aGVHD thanwomendid. Thiswas
not due to an increased aGVHD risk in those with heavier
weight or due to a greater risk in male patients engrafting
with female units. This observation concerning gender is of
great interest and remains unexplained.
The lack of difference in TRM between the low and high
MMF dosing groups may have been due to aggressive sup-
portive care administered to severe aGVHD cases. Addition-
ally, as one half of the 22 GVHD-related deaths were after day
180, this diluted the sample size to be able to identify dif-
ferences at day 180. This question of whether augmented
MMF dosing can reduce GVHD-related TRM is critically
important, however, and requires further investigation in a
larger study. Nonetheless, it is clear that the GVHD deaths in
this report were related to aGVHD, and in nearly all of these
patients the GVHD began before day 100. Therefore, aGVHD
is the correct target for prevention, and as severe aGVHD
increases patient morbidity and transplantation costs, it is a
serious complication to abrogate. Importantly, in relation to
other survival endpoints, increased MMF dosing was not
associated with an increase in deaths from infections or the
incidence of relapse.
Previous reports support the efﬁcacy of PK monitoring.
Studies suggest that higher MPA exposure from an increased
trough [23], steady-state concentration [24], or area under
the curve [25,26] results in a lower aGHVD incidence
although the ideal monitoring parameter has not been
established. In this study, a meanweek 1 and 2MPA trough
.5 mg/mL was hypothesized as clinically relevant for pro-
phylaxis given its relationship with therapeutic efﬁcacy [8].
We found that troughs < .5 mg/mL were associated with an
increased grade III and IV aGVHD risk, complementing the
ﬁndings of the larger 174 patient analysis. Moreover, that
dCBT recipients who received a low total daily MMF dose/kg
and had a low mean week 1 and 2 MPA trough had a very
high incidence of grade III and IV aGVHD demonstrates that
these patients, in particular, require increasedMPA exposure.
Although we did not identify an age effect in the 174 patient
analysis, young children are potentially at special risk, given
that patients < 16 years of age had lower troughs in our
analysis over the 6-week period, as expected given their
faster MMF metabolism [27]. Indeed, Osunkwo et al. have
proposed an increased MMF dosing to 900 to 1200 mg/m2
every 6 hours to achieve levels  1 mg/mL, which corre-
sponds to nearly 30 mg/kg/dose in children [23].
From the stand point of engraftment, an increased total
daily MMF dose per kilogram had no deleterious effect. For
this MPA trough level toxicity analysis, we choose a 2 mg/mL
cut-off based on solid organ transplantation literature [22].
The lack of any association between 1 to 2 week troughs and
engraftment supports the ﬁndings of the larger 174 patient
analysis. The upper threshold for total MPA troughs in CBT
has yet to be established, however, and the possible toxicity
of very high levels could remain a clinical concern. Although
Sanz et al. reported a delay in neutrophil engraftment with
the use of MMF compared with corticosteroids in patients
receiving single CBT [3], we have no evidence to indicate that
intensiﬁed dosing as investigated in this MSKCC analysis is
detrimental in dCBT. A potential risk of gastrointestinal
toxicity was also not substantiated, and there were no cases
of MMF colitis.
S. Harnicar et al. / Biol Blood Marrow Transplant 21 (2015) 920e925 925Multiple questions concerning MMF PK remain unan-
swered. Though the majority of our patients remained on i.v.
MMF for the duration of the PK subset period, the impact of
changing from i.v. to oral drug was not addressed in this
analysis and could be important given the potential drop in
bioavailability [28]. Additionally, whether intensiﬁed MMF
dosing later in the transplantation course can exacerbate
myelosuppression is possible, especially in the setting of
other myelosuppressive drugs, such as valganciclovir. Finally,
how to correctly taper MMF after transplantation is not
established. All of these questions require formal future
investigation.
This analysis supports intensiﬁed MMF dosing based on
the total daily dose per kilogram, even in adult dCBT re-
cipients receiving relatively low unit cell doses. As a recog-
nized adult dosage is 15 mg/kg/dose for patients < 50 kg, we
propose patients  50 kg also receive 15 mg/kg/dose every 8
hours with a dose cap of 1.5 gm every 8 hours. This inter-
vention could prove especially important in heavy patients
and/or recipients of highly HLA-mismatched units. Further-
more, although the ideal dosing in children less than 12 years
remains unknown, we now support intensiﬁed dosing of 30
mg/kg/dose (nearly 900 mg/m2/dose) as previously sug-
gested in Bhatia et al. [29] to optimize MPA exposure in this
population. Finally, obtainingMPA trough levels (ideally with
rapid result availability) during the ﬁrst 2 weeks after
transplantation to target a trough level  .5 mg/mL is also
appropriate in dCBT recipients.ACKNOWLEDGMENTS
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